Patient P-02172
Therapy response
Unstable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S02
- Day 65 SC-12 recommended — Supportive Compound SC-12
- Day 66 Patient declined — Not now
- Day 71 GI-04 recommended — GI Support Protocol GI-04
- Day 72 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 72 Patient accepted — Started GI-04 in the companion
- Day 78 ME-01 recommended — Monitoring Escalation ME-01
- Day 79 Patient accepted — Started ME-01 in the companion
- Day 80 No meaningful change — GI Support Protocol GI-04
- Day 82 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 72.
Primary contributors, last 14 days
- GI instability+31
- Inflammatory activity+25
- Nutritional resilience-11
- Toxicity+6
- Treatment adherence-3
What helped?
- Supportive Compound SC-12Day 65Declined by patient
- GI Support Protocol GI-04Day 71Result: no meaningful change
- Monitoring Escalation ME-01Day 78Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
64%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 64% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 84 and rising
- WearableSleep 5.0 h, below personal baseline
- Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 77
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 34/100
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓45
- WearableResting HR 86 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 53
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.2 · butyrate capacity 34/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 42 ms
- Sleep
- 5.0 h
- Steps
- 4,398
- Resting HR
- 84 bpm
Daily log: GI score 84, nutritional resilience 26, adherence 42.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02614 | 46% | S14 | — | — | 39 |
| P-02514 | 44% | S05 | ME-01 | improved | 44 |
| P-02571 | 43% | S11 | ME-01 | improved | 43 |
| P-02340 | 42% | S14 | NP-02 | no change | 46 |
| P-02546 | 42% | S20 | NP-02 | improved | 40 |
| P-02224 | 41% | S14 | NP-02 | no change | 33 |
| P-02511 | 41% | S04 | — | — | 51 |
| P-02610 | 41% | S14 | NP-02 | no change | 42 |
| P-02146 | 40% | S14 | ME-01 | improved | 33 |
| P-02372 | 40% | S14 | ME-01 | improved | 53 |
| P-02594 | 39% | S20 | — | — | 45 |
| P-02532 | 38% | S14 | — | — | 58 |